{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"596","upperLimit":"883","value":"719.5"},{"groupId":"OG001","lowerLimit":"470","upperLimit":"954","value":"666.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Absolute CD8 counts at cycle 5","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG000","title":"Phase I - Brentuximab 1.2 mg/kg"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG001","title":"Phase II - Brentuximab 1.2 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Participants with absolute CD8 counts at cycle 5","reportingStatus":"POSTED","timeFrame":"5 months","title":"CD8 Counts","type":"SECONDARY","unitOfMeasure":"cells/µL"}